

Deprescribing


this content is up-to-date as of
May 3, 2021



Wisconsin Alzheimer's Institute

UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

Learning objective



- Describe a strategy for gradual dose reductions of medications

Dose reductions of medications


- which medications should be discontinued
 - antipsychotics → benzodiazepines → other sedating medications
- how should medications be discontinued?
 - abrupt: most often studied, but would not recommend unless side effects are the reason for discontinuation
 - taper: less well studied, but seems to be expert consensus
 - antipsychotics: incremental reductions every 1-2 weeks until off
 - benzodiazepines: 10% per week
 - antidepressants: reverse of how they were initiated
- what if the target symptoms return?

Framework for deprescribing

Triggers to Deprescribe

1. Adverse drug reactions
2. Polypharmacy
3. Prescribing cascades
4. At end-of-life and as part of palliative care

*Framework and Process to Deprescribe



Dose reductions of medications: case

- 82-yo with dementia due to Alzheimer's disease whose agitation and paranoia have improved
- citalopram 20 mg qam, quetiapine 25 mg qam & 75 mg qhs, lorazepam 1 mg qhs, melatonin 5 mg qhs
- step 1: wean off quetiapine
 - d/c morning dose (sedation, risk of falls)
 - weekly intervals: 50 qhs → 25 qhs → d/c
- step 2: wean off lorazepam
 - weekly intervals: 0.5 qhs → (0.25 qhs) → d/c
- continue citalopram (unless side effects)
- d/c melatonin (unlikely effective)